

5 May 2026

## March Quarter Investor Video Presentation

**Emyria Limited (ASX: EMD)** (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to provide a March Quarter Video Presentation delivered by Executive Chairman Greg Hutchinson and Chief Operating Officer Mary-Ann Rennie. The focus of the presentation is:

- Review of Emyria’s key achievements for the March Quarter
- Discussion on Company opportunities and future catalysts
- An update on information regarding clinic utilisation for both Perth and Brisbane, as well as information regarding dosing and screening metrics up to 30 April 2026.

Attached is a slide presentation to accompany the video presentation.

**To view the March Quarter Video Presentation please click on the link below:**

<https://youtu.be/LJapqjhcTes>

*This release has been approved by the Board of Emyria.*

**For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact:**

**Greg Hutchinson**

**Executive Chair**

1300 436 363 | [investors@emyria.com](mailto:investors@emyria.com)

# emyria

**Emyria Limited** develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:

generates

**Emyria Healthcare:** Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

informs

**Emyria Data:** Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

**Emyria's Pipeline:** New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

## EMYRIA'S INTERACTIVE INVESTOR HUB

[Investorhub.emyria.com](https://investorhub.emyria.com) Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



**CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS** Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

## Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.

# emyria

ASX : EMD

## March Quarter Presentation

Investor Update

May 2026



# Disclaimer

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.

# Emyria | March Quarterly Highlights

Revenue growth - **\$1.2m** for the quarter

**Durable Clinical Outcomes** in PTSD program 12 months post treatment.  
**76% of patients** achieving **clinically significant** improvement  
**67% patients remained in remission**

First **Victorian Clinic** on track for **Q2 FY26 Commencement**  
Subsequently **announced first NSW Clinic** with Matilda Nepean Private Hospital


Launched **Global Partnership Program** targeting international Drug Sponsors  
**US signs Executive Order** to fast track psychedelic drug research and patient access<sup>1</sup>

<sup>1</sup> <https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/>

# Significant Global Research in Psychedelic Drugs

Many psychedelic-assisted therapy programs currently in development globally<sup>1</sup>

EMD uniquely positioned to support these companies through existing clinical network from clinical trial execution to post approval commercial roll-out<sup>2</sup>




1. Psychedelic Alpha, Psychedelic Drug Development Tracker: <https://psychedelicalpha.com/resources/psychedelic-drug-development-tracker/>

2 . Refer ASX announcement 20 April 2026

# Significant Global Research in Psychedelic Drugs

Personal use only



1. <https://psychedelics.berkeley.edu/clinical-trials-map>

# Regulatory Catalysts



Step	Description	Emyria's Mitigation
<b>Authorised Prescribers (APs) timeframes</b>	Extended Per-prescriber approvals process	Established HREC relationship & dedicated AP applications team.
<b>TGA</b>	Current limits on which disciplines can practise as PAT therapists.	Active advocacy to broaden eligible disciplines. Additional recruitment.
<b>DVA</b>	Funded, but restricted to 4th-line therapy with strict criteria.	Direct DVA engagement clarifying pre-treatment pathways.

Achieved

In discussion

Not achieved


## Authorised Prescriber Status

	Perth	Brisbane	Melbourne
<b># Approved AP's</b>	8	3	1
<b># Psychiatrists in process</b>	1	2	3


# New : Empax Clinic utilisation increasing



**Perth — 196 doses delivered as of 30 April 2026**



**Brisbane — 29 doses delivered as of 30 April 2026**



Personal use only

# Emyria (ASX:EMD) | Future Catalysts

Target activities



**Grow** capacity nationally  
via new site partners then  
**Optimise** utilisation of  
clinics



**New indications** to  
expand total addressable  
markets

**Expand** funded programs  
with new payers



**Add** new drug partners to  
Global Partnership Program

# Emyria | Why Invest



First mover advantage  
**globally**

Significant **Total  
Addressable Market**  
globally

**Operationalised** the  
delivery of PAT **at Scale**

**Capital Light** approach  
to clinics expansion

Delivering **durable**  
outcomes

Generating **revenue**

# Emyria Board

Significant Clinical Services & Global Innovation Expertise



**Greg Hutchinson**  
Executive Chairman

**Health Service Leadership:**

5D Clinics  
Former CEO Sonic HealthPlus leading 40+ clinics



**Dr Michael Winlo**  
Executive Director

**Research & Data Expertise:**

Ex-Palantir healthcare lead, Medical Doctor and Stanford MBA



**Dr Karen Smith**  
Non-Executive Director

**Biopharma Executive:**

100+ clinical trials and 20+ regulatory approvals; Former Chief Medical Officer and Global Head of R&D at Jazz Pharma



**Dr Mohit Kaushal**  
Non-Executive Director

**Health IT Strategist:**

Key role in Oak Street Health's \$10.6B acquisition by CVS Health; Served in Obama's Health IT task force; Adjunct Professor at Stanford



**Prof Sir John Tooke**  
Non-Executive Director  
**Clinical Service & Health Payer Expertise:**

Former President of the Academy of Medical Sciences, influential roles at BUPA and past advisor to Google DeepMind



# Contact Information



**Greg Hutchinson**

ghutchinson@emyria.com

**Mary-Ann  
Rennie**

mrennie@emyria.com

**Investor /  
Media Inquiries**

investors@emyria.com

**emyria**



**Visit Our  
Investor Hub**